Cyclerion Therapeutics (NASDAQ:KRSA) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Cyclerion Therapeutics (NASDAQ:KRSA) to a hold rating in a research report sent to investors on Wednesday morning,Zacks reports.

Cyclerion Therapeutics Trading Down 100.0%

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.